Loading...

World-Class Retina Care. Community-Based Caring.

Dr. Abbey Presented Study Results of Two Investigational Wet AMD Treatments at Clinical Trials Summit

Posted On June 24, 2025 / By / Posted in Blog

Dr. Abbey Presented Study Results of Two Investigational Wet AMD Treatments at Clinical Trials Summit

This past weekend, Texas Retina’s Director of Clinical Research for Dallas Ashkan M. Abbey, MD, led two presentations at the annual Clinical Trials at the Summit (CTS) meeting in Las Vegas, which

read more
Posted On June 16, 2025 / By / Posted in Blog

Initial Results of Phase Ib LOTUS Clinical Trial on Potential New Diabetic Macular Edema Treatment Released

On June 9, 2025, Eluminex Biosciences Limited, a clinical-stage protein therapeutics company, announced positive topline safety, tolerability, and pharmacodynamic data from the multicenter LOTUS Part 1 clinical trial of EB-105 in patients

read more
Posted On June 5, 2025 / By / Posted in Blog

Dr. Abbey Discusses How Vorolanib Could Shift the Treatment Approach for Diabetic Macular Edema in New Retinal Physician Article

Texas Retina’s Ashkan M. Abbey, MD, served as a principal site investigator for the Phase II VERONA clinical trial evaluating the efficacy and safety of the vorolanib intravitreal insert (EYP-1901) in diabetic

read more
Posted On April 29, 2025 / By / Posted in Blog

Dr. Abbey Shares 36-Month Results of Pegcetacoplan Treatment for Geographic Atrophy in AMD

On behalf of the investigators for the OAKS, DERBY, and GALE clinical trials, Texas Retina’s Director of Clinical Research for Dallas, Ashkan Abbey, MD, co-authored an article titled, “Pegcetacoplan Treatment for Geographic

read more
Posted On March 19, 2025 / By / Posted in Blog

Texas Retina Clinical Research Coordinator Rachel McCullough Participates in Panel Discussion for LUGANO and LUCIA Clinical Trials

At a recent meeting in San Antonio, Texas Retina Clinical Research Coordinator Rachel McCullough participated in a panel discussion with study coordinators for EyePoint Pharmaceuticals’ pivotal Phase III LUGANO and LUCIA clinical

read more
Posted On February 21, 2025 / By / Posted in Blog

Dr. Abbey Serves as Guest Editor for Latest Issue of Retina Today

Texas Retina’s Ashkan M. Abbey, MD, served as guest medical editor for the January/February 2025 issue of Retina Today along with Christina Y. Weng, MD, from Baylor College of Medicine. Retina Today

read more
Posted On February 12, 2025 / By / Posted in Blog

Dr. Abbey Discusses Injectable Retina Treatments on AAO Podcast

On a recent episode of the American Academy of Ophthalmology’s “Experts InSight” podcast, Texas Retina’s Ashkan Abbey, MD, joined Ehsan Rahimy, MD, and host Jay Shridhar, MD, to discuss recent developments in

read more
Posted On February 4, 2025 / By / Posted in Blog

Texas Retina Research Team Publishes New Study on Wet AMD Treatment

Texas Retina’s Ashkan Abbey, MD; Paige Abril, BS; and Rachel McCullough, BS, recently published a retrospective study in the peer-reviewed journal Ophthalmic Surgery, Lasers and Imaging Retina titled, “Outcomes of Intravitreal Aflibercept

read more
Posted On January 15, 2025 / By / Posted in Blog

Dr. Abbey Discusses Latest Dry AMD Treatment Research on New Podcast Episode

While anti-VEGF injections are widely used to treat patients with wet age-related macular degeneration (AMD), there have been limited treatment options available for dry AMD other than AREDS vitamin formulations and lifestyle

read more
Posted On December 17, 2024 / By / Posted in Blog

Dr. Abbey Reports on New Method to Measure Retinal Fluid After Treatment with Faricimab for Wet AMD

Texas Retina’s Ashkan M. Abbey, MD, recently co-authored an article in the medical journal Eye on the use of a novel deep-learning algorithm to quantify retinal fluid changes in patients treated with

read more